The Wegovy pill in brief: a once-daily 25 mg tablet

The "Wegovy pill" is Novo Nordisk's once-daily oral form of semaglutide, developed for weight management and taken as a tablet rather than a weekly injection[1]. The MHRA licensed it on 11 June 2026 as the first oral GLP-1 medicine for weight management in the UK[3]. The maintenance (target) dose is 25 mg once daily[1][2] — but nobody starts there. As with every GLP-1 medicine, the dose is climbed in steps.

The dose ladder: 1.5 mg up to 25 mg

According to the MHRA's announcement of the licence, the Wegovy tablet is titrated once daily through four levels — 1.5 mg, 4 mg, 9 mg and 25 mg — with a minimum of one month at each dose before moving up[3]. Starting low and rising slowly is standard practice for GLP-1 medicines: the most common side effects are gastrointestinal, and in the approval-supporting trial they were mostly mild-to-moderate and eased over time[6][10].

The UK titration ladder for the Wegovy pill, as set out in the MHRA's announcement of the licence.[3] The prescriber decides if and when each step happens.
StepOnce-daily doseMinimum time before the next step
Start1.5 mgAt least one month
24 mgAt least one month
39 mgAt least one month
Maintenance25 mg—

The 1.5 mg and 4 mg tablets are stepping stones, not destinations; 25 mg is the maintenance dose. "At least one month" is a minimum — a prescriber can hold a dose longer, or step back down, if side effects are a problem. Patients never adjust the dose themselves.

Switching from the Wegovy injection

Some people come to the tablet having already used the injectable form of Wegovy. The MHRA's announcement of the licence states that patients on the 2.4 mg once-weekly semaglutide injection can be transitioned directly to the 25 mg once-daily tablet[3] — without starting again at the bottom of the ladder. It remains a prescriber's decision. How the two routes compare is covered on our Wegovy pill vs injection page.

Don't confuse the pill's doses with Rybelsus or the trial doses

Three sets of milligram numbers get attached to oral semaglutide, and mixing them up is a common error:

  • The Wegovy pill (weight management): 1.5 mg → 4 mg → 9 mg → 25 mg once daily[3].
  • Rybelsus (type 2 diabetes): a separate, lower-dose oral semaglutide. Its newer tablets come in 1.5 mg, 4 mg and 9 mg — the same numbers as the Wegovy pill's first three steps — and replaced its original 3 mg, 7 mg and 14 mg tablets in the UK during 2025–26[11]. It is the same molecule delivered the same way, but a distinct product with a different ladder and licensed use.
  • The research doses: the OASIS obesity trials tested 25 mg and 50 mg, and an earlier 50 mg read-out reported an average weight change of about −15.1% versus −2.4% on placebo[5]. The approved tablet is 25 mg, not 50 mg. OASIS 4 itself stepped up through 3 mg, 7 mg and 14 mg tablets before 25 mg, according to its trial registry record[12] — original-formulation tablets shown to be bioequivalent to the 1.5 mg, 4 mg and 9 mg steps in the UK licence[13].

How to take the Wegovy pill: the empty-stomach rules

The instruction is one tablet a day, but the timing around it is unusually strict — for good reason (below). The MHRA's announcement of the licence and the UK product information set it out as follows[3][10]:

  • Once daily, first thing in the morning, on an empty stomach after fasting overnight — at least 8 hours without food[3].
  • With plain water only. MHRA messaging describes taking it with a sip of water[3]; the established labelling for oral semaglutide specifies no more than about 120 mL (roughly four ounces)[4]. Either way: a small amount of plain water, nothing else.
  • Then wait at least 30 minutes before eating, drinking anything else, or taking any other medicine[3][10].

The tablet should be swallowed whole — not split, crushed or chewed; the UK product information notes it is not known whether breaking it up affects how the semaglutide is absorbed[10]. Our guide to why the empty-stomach rule exists explains the reasoning behind the routine in more detail.

Why the timing is not optional

Oral semaglutide is not absorbed like an ordinary tablet: how much of the dose reaches the body depends heavily on taking it exactly as directed. That is why the labelling is so specific — an empty stomach, only a small amount of plain water, and no food, other drinks or other medicines for at least 30 minutes afterwards[4]. Taking it with food, with more water than allowed, or alongside other tablets too soon means less of the dose is absorbed. Get the routine wrong and you are lowering the effective dose, not just bending a rule.

Why taking it correctly matters: adherence and results

Because absorption depends so heavily on the daily routine, consistency is part of the treatment. The approval-supporting OASIS 4 trial of the 25 mg tablet showed this clearly. Measured as the effect if the medicine is taken fully as directed, average weight loss was about −16.6% versus −2.8% on placebo[1][10]. Measured across everyone regardless of how well they stuck to it, the average was about −13.6% versus −2.2% on placebo, according to the UK product information[10]. Around 76% of people on the tablet lost at least 5% of their body weight versus 31% on placebo[2], and Novo Nordisk reports roughly one in three reached at least 20%[1]. The gap between those two headline figures — taken perfectly versus taken as people really manage — is the case for getting the daily habit right.

Side effects during titration, and how to report them

Because the dose is climbed rather than started high, the toughest patch is usually the escalation phase. In OASIS 4, gastrointestinal effects — nausea, diarrhoea, vomiting, constipation and stomach pain among them — were reported by about 74% of people on the tablet versus 42% on placebo, mostly mild-to-moderate and easing over time[6][10]. Discontinuation because of side effects was low and close to placebo, at about 7% versus 6%[2]. Our Wegovy pill side effects page goes through the full list and who should not take it.

Report side effects

If you experience side effects from any medicine, report them through the MHRA Yellow Card scheme[7] and speak to your GP or pharmacist. Severe, persistent stomach pain, signs of dehydration from vomiting or diarrhoea, or any symptom that worries you are reasons to get medical advice rather than keep pushing on with the dose.

Storage and missed doses

The definitive storage and missed-dose instructions belong to the patient information leaflet and your pharmacist, not a website. The UK leaflet says to keep tablets in the original pack to protect them from light and moisture, and out of the sight and reach of children. They need no special temperature storage, so, unlike some injectable treatments, they do not need to go in the fridge[8]. If you miss a dose, skip it and take your normal dose the next day — never take two tablets to make up for it[8].

Getting it in the UK

The Wegovy pill is a prescription-only medicine. Since the June 2026 MHRA licence it can be prescribed privately following a proper consultation, but it is not funded on the NHS; NHS access would require a separate NICE technology appraisal, which had not concluded when the medicine was licensed[3]. NICE has already restricted NHS use of injectable semaglutide to defined patient groups rather than open access[9] — a fair indication of how the pill may be handled if recommended, though nothing is confirmed yet.

The licensed use is broadly for adults living with obesity, or with overweight alongside a weight-related health condition, as an add-on to a reduced-calorie diet and more physical activity[1][2]. Whether that applies to a given person is for a prescriber to decide, and anyone who could become pregnant should discuss it with their prescriber, as semaglutide is not for use in pregnancy. We do not sell, supply or recommend any provider; lawful UK supply runs through GPhC-registered pharmacies against a valid prescription only.

Frequently asked questions

How do you take the Wegovy pill?

One tablet a day, swallowed whole, first thing on an empty stomach after fasting overnight (at least 8 hours), with plain water only — then wait at least 30 minutes before eating, drinking anything else, or taking any other medicine[3][10]. These rules are what allow the semaglutide to be absorbed.

What is the maximum dose of the Wegovy pill?

The maintenance and target dose is 25 mg once daily, the top of the ladder[1][3]. Treatment starts at 1.5 mg and is stepped up by a prescriber, with at least one month at each level[3].

Do you take the Wegovy pill on an empty stomach?

Yes — first thing, after fasting overnight, with only plain water, then a wait of at least 30 minutes before anything else[3]. Those timing rules match the established labelling for oral semaglutide[4], and following them exactly is what allows the medicine to be absorbed properly — taking it with food, too much water, or other tablets too soon lowers how much of the dose gets in.

Is the Wegovy pill the same as Rybelsus?

Both are oral semaglutide, but they are different products. Rybelsus (now 1.5 mg, 4 mg and 9 mg tablets, which replaced its 3 mg, 7 mg and 14 mg strengths) is licensed for type 2 diabetes[11]; the Wegovy pill is a higher-dose oral semaglutide (up to 25 mg) for weight management. Even where the milligram numbers match, the tablets are not interchangeable.

Is the Wegovy pill better than the injection?

It is not a matter of better or worse — both contain the same molecule. The pill is taken by mouth daily with strict timing; the injection is given weekly under the skin. Which route suits someone is a prescriber's decision, and people on the 2.4 mg weekly injection can switch directly to the 25 mg daily tablet[3]. See our pill vs injection page.

What should I do if I miss a dose?

Skip the missed dose and take your normal dose the next day, as the UK patient leaflet advises; do not take an extra tablet to make up for it[8]. If you have missed several days, ask your prescriber or pharmacist how to carry on.

Further reading

References

  1. Novo Nordisk. Wegovy (oral semaglutide 25 mg) regulatory approval — company announcement: first oral GLP-1 for weight management; OASIS 4 trial-product weight loss; proportion reaching at least 20%. novonordisk.com
  2. US Food and Drug Administration. Wegovy (semaglutide) injection and tablets — US Prescribing Information, revised 06/2026 (via DailyMed): the 25 mg maintenance dose and licensed use; the 25 mg tablet trial results (at least 5% weight loss in 76.3% vs 31.3% on placebo); and 6.9% vs 5.9% of patients stopping treatment because of adverse reactions. dailymed.nlm.nih.gov
  3. Medicines and Healthcare products Regulatory Agency (MHRA) / GOV.UK. "First GLP-1 tablet for weight loss approved in the UK" — press release, 11 June 2026: the UK licence date, the dose ladder (1.5 mg, 4 mg, 9 mg and 25 mg, with a minimum of one month at each dose), the taking-it rules (on an empty stomach after fasting for at least 8 hours, with a sip of water, then no food or drink for at least 30 minutes), the direct switch from the 2.4 mg once-weekly injection to the 25 mg once-daily tablet, and the NHS position (not currently available on the NHS; decisions on NHS use to follow established processes, including a NICE evaluation). gov.uk
  4. US Food and Drug Administration. Rybelsus (oral semaglutide) prescribing information (2024) — the oral-semaglutide administration rules (empty stomach, plain water no more than 120 mL, wait at least 30 minutes). accessdata.fda.gov
  5. The Lancet. OASIS 1 — oral semaglutide 50 mg in adults with overweight or obesity (2023). thelancet.com
  6. Wharton S, Lingvay I, Bogdanski P, et al. "Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity" (OASIS 4). New England Journal of Medicine, 18 September 2025;393:1077–1087 — trial design and gastrointestinal adverse events (74.0% vs 42.2% with placebo). doi.org/10.1056/NEJMoa2500969 Trial registration: ClinicalTrials.gov NCT05564117. clinicaltrials.gov
  7. MHRA. Yellow Card scheme — report a side effect. yellowcard.mhra.gov.uk
  8. Novo Nordisk. Wegovy tablets — UK patient information leaflet (revised 06/2026): section 3, "If you forget to take wegovy" (skip the missed dose and take the normal dose the next day), and section 5, storage (keep in the original package to protect from light and moisture; no special temperature storage conditions). medicines.org.uk
  9. NICE. Technology appraisal TA875 — semaglutide (injectable) for managing overweight and obesity (context for the pill's likely NHS route). nice.org.uk
  10. Novo Nordisk. Wegovy 25 mg tablets — UK Summary of Product Characteristics: section 4.2 (take on an empty stomach after fasting for at least 8 hours, swallowed whole with a sip of water of up to 120 mL, then wait at least 30 minutes before eating, drinking or taking other oral medicines; tablets should not be split, crushed or chewed, as it is not known whether this impacts absorption), section 4.8 (gastrointestinal side effects most frequent during dose escalation, mostly mild to moderate and of short duration) and section 5.1, Table 2 (OASIS 4 body-weight change at week 64: −13.6% vs −2.2% with placebo, treatment-policy analysis; −16.6% vs −2.8% if all patients had stayed on treatment); text revised 06/2026. medicines.org.uk
  11. Medicines and Healthcare products Regulatory Agency (MHRA). Drug Safety Update, "Rybelsus® (semaglutide tablets): transition to new formulation and risk of medication error", 17 December 2025 — Rybelsus is for adults with type 2 diabetes; new 1.5 mg, 4 mg and 9 mg tablets are bioequivalent to, and replace, the original 3 mg, 7 mg and 14 mg tablets, with the original formulation expected to be available until about 31 January 2026. gov.uk
  12. ClinicalTrials.gov. NCT05564117 — OASIS 4 registry record: dose escalation of 3 mg (weeks 0–4), 7 mg (weeks 5–8) and 14 mg (weeks 9–12), then 25 mg (weeks 13–64). clinicaltrials.gov
  13. European Medicines Agency. Wegovy — EPAR assessment report for the tablet extension (X/0000296344), published 26 August 2026: OASIS 4 escalated through the original 3 mg, 7 mg and 14 mg oral semaglutide tablets, which study NN9924-4799 showed to be bioequivalent to the 1.5 mg, 4 mg and 9 mg tablets now marketed; the 25 mg tablet is the same formulation used in OASIS 4. ema.europa.eu